Table 3.
Adverse events through 3 months.
| Adverse events | Control group (n=94), n (%) | Intervention group (n=145), n (%) | P value | ||
| Any adverse events | 8 (9) | 18 (12.4) | .35 | ||
|
|
Elevated liver enzymes | 5 (5) | 12 (8.3) |
|
|
|
|
Renal impairment | 2 (2) | 1 (0.7) |
|
|
|
|
Mild hypoglycemia | 0 (0) | 5 (3.5) |
|
|
|
|
Serious adverse events |
|
|
|
|
|
|
|
Death | 1 (1)a | 0 (0) |
|
aDeath from cerebral infarction.